Drug intelligence / Profile preview

Tretazicar

Development stage: Preclinical
Lead developer: BTG International
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intraperitoneal, Oral

Overview

Tretazicar (CB1954) is an antitumor prodrug that is enzymatically activated to generate a bifunctional agent. This activated form creates DNA-DNA interstrand cross-links, which inhibits DNA replication and induces apoptosis in cancer cells. Its activation involves the reduction of its 4-nitro group to a 4-hydroxylamine by enzymes such as NAD(P)H:quinone oxidoreductase 1 (NQO1) or NAD(P)H quinone oxidoreductase 2 (NQO2). Tretazicar has been investigated for its potential in Gene-Directed Enzyme Prodrug Therapy (GDEPT) and has shown selectivity against certain tumor lines.

Other names: 5-(aziridin-1-yl)-2,4-dinitrobenzamide

Targets

NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])NQO1DNA

Beyond the preview

Go deeper on Tretazicar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tretazicar.

Explore the full profile